JP2008523083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523083A5 JP2008523083A5 JP2007545628A JP2007545628A JP2008523083A5 JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5 JP 2007545628 A JP2007545628 A JP 2007545628A JP 2007545628 A JP2007545628 A JP 2007545628A JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- target
- multispecific
- targets
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 6
- 230000000770 proinflammatory effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 3
- 239000003114 blood coagulation factor Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 210000005007 innate immune system Anatomy 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 210000005006 adaptive immune system Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000008938 immune dysregulation Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63407604P | 2004-12-08 | 2004-12-08 | |
| PCT/US2005/044446 WO2006063150A2 (en) | 2004-12-08 | 2005-12-08 | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248395A Division JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523083A JP2008523083A (ja) | 2008-07-03 |
| JP2008523083A5 true JP2008523083A5 (enExample) | 2009-02-12 |
Family
ID=36578580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545628A Pending JP2008523083A (ja) | 2004-12-08 | 2005-12-08 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| JP2012248395A Pending JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248395A Pending JP2013079240A (ja) | 2004-12-08 | 2012-11-12 | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US8420783B2 (enExample) |
| EP (1) | EP1819731A4 (enExample) |
| JP (2) | JP2008523083A (enExample) |
| AU (1) | AU2005313971B2 (enExample) |
| CA (1) | CA2587143C (enExample) |
| WO (1) | WO2006063150A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7148038B2 (en) * | 2001-10-16 | 2006-12-12 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| AU2007317333A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| RU2473563C2 (ru) * | 2007-06-07 | 2013-01-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ |
| US20110142837A1 (en) * | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8940299B2 (en) * | 2008-02-28 | 2015-01-27 | Case Western Reserve University | Method of treating cancer |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| RU2474588C2 (ru) | 2008-05-05 | 2013-02-10 | Новиммун Са | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| US20100278829A1 (en) * | 2009-02-06 | 2010-11-04 | Edwards Iii Carl Keith | Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members |
| CA2766565A1 (en) * | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| BR112012004546A8 (pt) | 2009-08-29 | 2017-12-05 | Abbott Lab | Terapêutica por proteínas ligantes dll4-ligantes |
| US20120315267A1 (en) * | 2010-02-09 | 2012-12-13 | Glaxosmithkline Llc | Novel uses |
| KR101853278B1 (ko) | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | 치료학적 ｄｌｌ４ 결합 단백질 |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| EP2726506A1 (en) * | 2011-05-27 | 2014-05-07 | Dutalys | Removal of monomeric targets |
| JP2013040160A (ja) * | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| ES2758923T3 (es) * | 2011-12-12 | 2020-05-07 | Vascular Biogenics Ltd | Tratamiento de esteatohepatitis no alcohólica |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| WO2014028862A1 (en) | 2012-08-17 | 2014-02-20 | Cornell University | Use of dna in circulating exosomes as a diagnostic marker for metastasic disease |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| EP2912068B1 (en) | 2012-10-26 | 2019-06-19 | Deutsches Rheuma-Forschungszentrum Berlin | Bi-specific antibodies for cell-lineage-specific tnf-alpha neutralisation |
| TW202037609A (zh) | 2012-11-01 | 2020-10-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2014117220A1 (en) * | 2013-02-01 | 2014-08-07 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
| EP3125907A4 (en) | 2014-04-01 | 2017-11-29 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
| US10351621B2 (en) | 2014-06-24 | 2019-07-16 | Immunomedics, Inc. | Anti-histone therapy in acute kidney injury |
| EP3160504B1 (en) * | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| US10278986B2 (en) * | 2014-08-14 | 2019-05-07 | The Regents Of The University Of Colorado, A Body Corporate | Antibody-siRNA conjugates and uses therefor |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| SI3215527T1 (sl) | 2014-11-05 | 2025-04-30 | Annexon, Inc. | Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| EP3865139B1 (en) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CA2981321A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| US10738118B2 (en) | 2015-05-29 | 2020-08-11 | Amphivena Therapeutics, Inc. | Methods of using bispecific CD33 and CD3 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物 |
| WO2019241216A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| WO2020077258A1 (en) * | 2018-10-12 | 2020-04-16 | Jeanmarie Guenot | Cd33×cd3 binding proteins for treating inflammatory conditions and diseases |
| AU2019412561A1 (en) | 2018-12-24 | 2021-08-12 | Sanofi | Multispecific binding proteins with mutant Fab domains |
| IL319262A (en) | 2018-12-24 | 2025-04-01 | Sanofi Sa | Multispecific FAB pseudoproteins bind |
| KR20210126641A (ko) | 2019-02-12 | 2021-10-20 | 리제너론 파아마슈티컬스, 인크. | 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법 |
| WO2020185685A1 (en) * | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| US5256770A (en) * | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| GB8918232D0 (en) | 1989-08-10 | 1989-09-20 | Opal Stephen M | Pharmaceutical product for the treatment of septic shock |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| JP4708510B2 (ja) | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ，インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US5830448A (en) * | 1994-06-16 | 1998-11-03 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| DE69519929T2 (de) | 1994-07-11 | 2001-05-23 | Board Of Regents, The University Of Texas System | Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen |
| US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| ATE473242T1 (de) * | 1998-05-20 | 2010-07-15 | Immunomedics Inc | Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| MXPA01002580A (es) * | 1998-09-10 | 2002-04-08 | Univ Virginia | Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas. |
| EP1319025A2 (en) * | 2000-09-07 | 2003-06-18 | John R. Schreiber | Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| US20020192217A1 (en) * | 2001-03-07 | 2002-12-19 | Thierry Calandra | Methods for regulation of immune responses to conditions involving mediator-induced pathology |
| JP2005518336A (ja) * | 2001-06-26 | 2005-06-23 | イムクローン システムズ インコーポレイティド | Ｖｅｇｆ受容体に結合する二重特異性抗体 |
| EP1416945A4 (en) * | 2001-07-17 | 2006-02-22 | Univ Virginia | IMPROVED HETEROPOLYMER COMPLEXES AND METHOD FOR THEIR USE |
| WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| AU2003295330A1 (en) * | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US7438907B2 (en) * | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| NZ541050A (en) * | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| EP2266606B1 (en) | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| WO2005102456A1 (en) * | 2004-03-27 | 2005-11-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| ES2665422T3 (es) * | 2005-03-03 | 2018-04-25 | Immunomedics Inc. | Anticuerpos L243 humanizados |
| ES3000111T3 (en) * | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
-
2005
- 2005-12-08 AU AU2005313971A patent/AU2005313971B2/en not_active Ceased
- 2005-12-08 EP EP05853383A patent/EP1819731A4/en not_active Ceased
- 2005-12-08 JP JP2007545628A patent/JP2008523083A/ja active Pending
- 2005-12-08 US US11/296,432 patent/US8420783B2/en not_active Expired - Fee Related
- 2005-12-08 CA CA2587143A patent/CA2587143C/en not_active Expired - Fee Related
- 2005-12-08 WO PCT/US2005/044446 patent/WO2006063150A2/en not_active Ceased
-
2007
- 2007-10-30 US US11/929,279 patent/US8420786B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,221 patent/US20080108794A1/en not_active Abandoned
- 2007-10-30 US US11/929,315 patent/US20080241141A1/en not_active Abandoned
-
2012
- 2012-04-09 US US13/442,504 patent/US20120230953A1/en not_active Abandoned
- 2012-11-12 JP JP2012248395A patent/JP2013079240A/ja active Pending
- 2012-11-16 US US13/678,832 patent/US20130177498A1/en not_active Abandoned
- 2012-12-17 US US13/717,230 patent/US20130123473A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523083A5 (enExample) | ||
| Briasoulis et al. | The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure | |
| Koenig et al. | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape | |
| Shenoy et al. | Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models | |
| Foss et al. | TRIM 21: a cytosolic Fc receptor with broad antibody isotype specificity | |
| JP2019520550A5 (enExample) | ||
| Linke et al. | Activated platelets induce an anti‐inflammatory response of monocytes/macrophages through cross‐regulation of PGE2 and cytokines | |
| ES2688941T3 (es) | Antagonistas del receptor 1 del factor de necrosis tumoral para tratar enfermedades respiratorias | |
| WO2006063150A3 (en) | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer | |
| JP2017113019A5 (enExample) | ||
| JP2022109909A (ja) | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法 | |
| Wu et al. | A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo | |
| Lech et al. | Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments | |
| Hong et al. | Macrophage regulation of graft-vs-host disease | |
| Scott et al. | Inflammasomes: a novel therapeutic target in pulmonary hypertension? | |
| JP2005512507A5 (enExample) | ||
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| CN102099378A (zh) | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 | |
| Gianni et al. | Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review | |
| WO2008106980A3 (en) | Recombinant antibodies for treatment of respiratory syncytial virus infections | |
| JP6535139B2 (ja) | Ｉｌ−１７ｃに対する抗体 | |
| Yu et al. | Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-ΚB pathway | |
| JP2023532272A5 (enExample) | ||
| EA201290172A1 (ru) | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 | |
| Zhang et al. | New insight into the pathogenesis of minimal change nephrotic syndrome: role of the persistence of respiratory tract virus in immune disorders |